Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136343 | 0.86 | TSHR (0.81) | ALDH1A1RECQLTSHRPOLBGAA | |
| SCHEMBL13649464 | 0.85 | MAPT (0.72) | ALDH1A1RECQLTSHRPOLBL3MBTL1 | |
| SCHEMBL16133680 | 0.85 | ALDH1A1 (1.00) | ALDH1A1RECQLTSHRPOLBL3MBTL1 | |
| SCHEMBL23638514 | 0.82 | NPC1 (0.57) | ALDH1A1RECQLTSHRPOLBL3MBTL1 | |
| SCHEMBL3539326 | 0.82 | ALDH1A1 (0.72) | ALDH1A1RECQLTSHRPOLBL3MBTL1 | |
| SCHEMBL18381424 | 0.81 | TSHR (0.76) | ALDH1A1RECQLTSHRPOLBGAA | |
| SCHEMBL19265679 | 0.80 | ALDH1A1 (0.62) | ALDH1A1RECQLTSHRPOLBL3MBTL1 | |
| SCHEMBL9696974 | 0.80 | RAB9A (0.55) | ALDH1A1RECQLTSHRPOLBL3MBTL1 | |
| SCHEMBL16768668 | 0.80 | ALDH1A1 (0.73) | ALDH1A1RECQLTSHRL3MBTL1GAA | |
| SCHEMBL10064150 | 0.79 | ALDH1A1 (0.60) | ALDH1A1RECQLTSHRPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9365570-B2 | Substituted 6, 5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | ALDH1A1 594/4885RECQL 870/4885TSHR 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.